Details

NameSymbolSector
PARMAX PHARMA LIMITEDPARMAXPharmaceuticals
Open
29.9
High
29.9
Low
28.44
Close
28.44
Volume
498
Exchange
bse
Time
30-Mar-2026

Outlook

Score:  

2

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Parmax Pharma is  
Marubozu
Estimated Stoploss of Parmax Pharma is ₹  
29.9
Parmax Pharma has a  
Bearishℹ
 pattern. 
Formation of  
Marubozu
 candle pattern indicates Parmax Pharma has chances of  
Continuationℹ
 of the current trend. 

Trend

Parmax Pharma is in  
Sideways trendℹ
. 
Price of Parmax Pharma is  
Downℹ
 by  

6.69

%. 
Target
Buy @ 

25.46

Sell @ 

38.56

Current @ 

28.44

Volume

The trade volumes of Parmax Pharma have become  
Deficientℹ
The volume trend for Parmax Pharma is  
Bearishℹ
, but the participants are  
Weak Sellersℹ
The trade volume of Parmax Pharma is  

Down

 by  

70.97

% 

Valuation

The current market price of Parmax Pharma is  
Undervaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 18cr and total assets worth ₹ 18cr, the balance sheet of Parmax Pharma is:  
Balancedℹ
. 
Cashflow
Parmax Pharma has  
Insufficientℹ
 cash flow because it is  

₹ 0cr

. It is  
Downℹ
 by  

0

%. 

(*Mar 2025)

0% in operatingℹ
0% in investingℹ
100% i.e. ₹ 1cr earned in financingℹ
0% in otherℹ
Parmax Pharma has  
Insufficientℹ
 cash flow because it is  

₹ 0cr

. It is  
Downℹ
 by  

0

%. 

(*Mar 2024)

0% in operatingℹ
50% i.e. ₹ 1cr spent in investingℹ
50% i.e. ₹ 1cr earned in financingℹ
0% in otherℹ
Income
The income of Parmax Pharma is  

₹ 2cr

 and  

Loss

 is :  

₹ 2cr

(*Sep 2025)

Parmax Pharma Losses increased by:  

200

% and Income is Up by:  

100

% 

(*Sep 2025)

The income of Parmax Pharma is  

₹ 1cr

 and  

Loss

 is :  

₹ 0cr

(*Jun 2025)

Parmax Pharma Losses decreased by:  

100

% and Income is Down by:  

75

% 

(*Jun 2025)

The income of Parmax Pharma is  

₹ 4cr

 and  

Loss

 is :  

₹ 1cr

(*Mar 2025)

Parmax Pharma Losses increased by:  

100

% and Income is Down by:  

33.33

% 

(*Mar 2025)

By using this site you agree to the use of cookies to deliver a better site experience.